Contact
searchSearch
HMP Global
Login

Bladder Cancer Resource Center

FDA Approval
FDA Approves Erdafitinib for Patients With Locally Advanced/Metastatic Urothelial Carcinoma Harboring FGFR3 Alterations
01/20/2024
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1...
01/20/2024
Oncology
From Oncology
News
Endoluminal Gemcitabine-Docetaxel as a Renal-Sparing Option for Select Patients With High Grade Upper-Tract Urothelial Carcinoma
01/08/2024
According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.
According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.
According to a retrospective...
01/08/2024
Oncology
From Oncology
David Bogumil
Videos
Multiple Ethnicities Study Explores A Connection Between Type 2 Diabetes and Urinary Bladder Cancer
10/12/2023
David Bogumil, PhD, details his findings on a connection between type 2 diabetes and urinary bladder cancer for African American, European American, Japanese American, Latin American, and Native Hawaiian populations.
David Bogumil, PhD, details his findings on a connection between type 2 diabetes and urinary bladder cancer for African American, European American, Japanese American, Latin American, and Native Hawaiian populations.
David Bogumil, PhD, details his...
10/12/2023
Journal of Clinical Pathways
Conference Coverage
Outcomes and Costs of Treatment for Patients With Metastatic Upper Tract Urothelial Carcinoma
03/31/2023
At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
At the 2023 ASCO GU Cancers...
03/31/2023
Journal of Clinical Pathways
Guideline Updates
NCCN Updates Therapy Guidelines in Bladder Cancer
08/26/2022
NCCN Guidelines Panel for Bladder Cancer presented data evaluating new treatment options in bladder cancer, as well as relevant updates to the NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer.
NCCN Guidelines Panel for Bladder Cancer presented data evaluating new treatment options in bladder cancer, as well as relevant updates to the NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer.
NCCN Guidelines Panel for...
08/26/2022
Journal of Clinical Pathways
News
Increased Costs Associated With Excessive Surveillance and Treatment For Non–Muscle-Invasive Bladder Cancer
04/14/2022
The annual median one-year cost of care for low-grade, non–muscle-invasive bladder cancer increased by 60%, or nearly $20,000, from 2004 to 2013, according to a population-based cohort study.
The annual median one-year cost of care for low-grade, non–muscle-invasive bladder cancer increased by 60%, or nearly $20,000, from 2004 to 2013, according to a population-based cohort study.
The annual median one-year cost...
04/14/2022
Journal of Clinical Pathways
Overactive Bladder Health Care Burden in the US Long-Term Care Setting: A Retrospective Cohort Study
Research Reports
Overactive Bladder Health Care Burden in the US Long-Term Care Setting: A Retrospective Cohort Study
05/18/2021
Richard Stefanacci, DO, and colleagues describe and evaluate the population, treatment patterns, HCRU, and costs associated with overactive bladder in the in the US long-term care setting.
Richard Stefanacci, DO, and colleagues describe and evaluate the population, treatment patterns, HCRU, and costs associated with overactive bladder in the in the US long-term care setting.
Richard Stefanacci, DO, and...
05/18/2021
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for Bladder Cancer
Guideline Updates
NCCN Updates Clinical Practice Guideline for Bladder Cancer
03/24/2021
NCCN updated its clinical practice guideline for bladder cancer, removing atezolizumab as an alternative second-line systemic therapy option for locally advanced or metastatic disease.
NCCN updated its clinical practice guideline for bladder cancer, removing atezolizumab as an alternative second-line systemic therapy option for locally advanced or metastatic disease.
NCCN updated its clinical...
03/24/2021
Journal of Clinical Pathways
Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma
Videos
Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma
03/12/2021
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses...
03/12/2021
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for Bladder Cancer
Guideline Updates
NCCN Updates Clinical Practice Guideline for Bladder Cancer
03/10/2021
On March 9, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for bladder cancer.
On March 9, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for bladder cancer.
On March 9, 2021, the National...
03/10/2021
Journal of Clinical Pathways
Study Finds No Correlation Between Antibiotic Use and OS in Metastatic Urothelial Carcinoma
Videos
Study Finds No Correlation Between Antibiotic Use and OS in Metastatic Urothelial Carcinoma
02/19/2021
Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.
Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.
Shilpa Gupta, MD, discusses the...
02/19/2021
Journal of Clinical Pathways

Expert Insights

David Bogumil
Videos
Multiple Ethnicities Study Explores A Connection Between Type 2 Diabetes and Urinary Bladder Cancer
10/12/2023
David Bogumil, PhD, details his findings on a connection between type 2 diabetes and urinary bladder cancer for African American, European American, Japanese American, Latin American, and Native Hawaiian populations.
David Bogumil, PhD, details his findings on a connection between type 2 diabetes and urinary bladder cancer for African American, European American, Japanese American, Latin American, and Native Hawaiian populations.
David Bogumil, PhD, details his...
10/12/2023
Journal of Clinical Pathways
Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma
Videos
Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma
03/12/2021
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses...
03/12/2021
Journal of Clinical Pathways
Study Finds No Correlation Between Antibiotic Use and OS in Metastatic Urothelial Carcinoma
Videos
Study Finds No Correlation Between Antibiotic Use and OS in Metastatic Urothelial Carcinoma
02/19/2021
Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.
Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.
Shilpa Gupta, MD, discusses the...
02/19/2021
Journal of Clinical Pathways
Adoption of Avelumab for First-Line Maintenance Therapy of Urothelial Cancer in US
Videos
Adoption of Avelumab for First-Line Maintenance Therapy of Urothelial Cancer in US
02/18/2021
02/18/2021
Journal of Clinical Pathways
Pembrolizumab Unlikely Cost-Effective for BCG-Unresponsive Bladder Cancer in US
Videos
Pembrolizumab Unlikely Cost-Effective for BCG-Unresponsive Bladder Cancer in US
02/17/2021
02/17/2021
Journal of Clinical Pathways
Davids Headshot
Interview
Integrating Real-World Evidence and Clinical Trial Data in CLL Management
01/17/2025
In this interview, Matthew S. Davids, MD, MMSc, discusses the role of real-world evidence in chronic lymphocytic leukemia (CLL) management, treatment considerations for high-risk and comorbid patients, strategies for therapy discontinuation,...
In this interview, Matthew S. Davids, MD, MMSc, discusses the role of real-world evidence in chronic lymphocytic leukemia (CLL) management, treatment considerations for high-risk and comorbid patients, strategies for therapy discontinuation,...
In this interview, Matthew S....
01/17/2025
Journal of Clinical Pathways
Romano Headshot
Interview
Personalizing Radiotherapy for Endometrial Cancer: Balancing Innovation and Quality of Life
01/17/2025
In this interview, Kara D. Romano, MD, University of Virginia, discusses advancements in radiation therapy for endometrial cancer, the integration of systemic therapies, the impact of treatment on quality of life, and the role of clinical...
In this interview, Kara D. Romano, MD, University of Virginia, discusses advancements in radiation therapy for endometrial cancer, the integration of systemic therapies, the impact of treatment on quality of life, and the role of clinical...
In this interview, Kara D....
01/17/2025
Journal of Clinical Pathways
Ma Headshot
Interview
Advancing Biomarker Validation and Emerging Treatments in Metastatic Breast Cancer
01/16/2025
In this interview, Cynthia X. Ma, MD, PhD, Washington University School of Medicine, discusses challenges in biomarker validation, the role of combination therapies, promising novel agents, and the integration of emerging treatments for...
In this interview, Cynthia X. Ma, MD, PhD, Washington University School of Medicine, discusses challenges in biomarker validation, the role of combination therapies, promising novel agents, and the integration of emerging treatments for...
In this interview, Cynthia X....
01/16/2025
Journal of Clinical Pathways
Bhat Headshot
Interview
Novel Therapies and Their Impact on Treatment Pathways for Chronic Lymphocytic Leukemia
01/13/2025
In this interview, Seema A. Bhat, MD, discusses the evolving treatment landscape for chronic lymphocytic leukemia, including strategies for treatment selection, sequencing, addressing diagnostic gaps, and exploring novel therapies to improve...
In this interview, Seema A. Bhat, MD, discusses the evolving treatment landscape for chronic lymphocytic leukemia, including strategies for treatment selection, sequencing, addressing diagnostic gaps, and exploring novel therapies to improve...
In this interview, Seema A....
01/13/2025
Journal of Clinical Pathways
Meisel Headshot
Interview
Improving Early Detection and Treatment for Breast Cancer Patients
01/10/2025
In this interview, Jane L. Meisel, MD, discusses advancements in early breast cancer detection, the integration of standard and emerging treatments, strategies for improving patient adherence, and opportunities for optimizing care through...
In this interview, Jane L. Meisel, MD, discusses advancements in early breast cancer detection, the integration of standard and emerging treatments, strategies for improving patient adherence, and opportunities for optimizing care through...
In this interview, Jane L....
01/10/2025
Journal of Clinical Pathways
BDHC Thumbnail
Videos
Alternative Payment Models in Health Care: Successes, Failures, and What’s Next
01/09/2025
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the evolution and challenges of alternative payment models, including accountable care organizations (ACOs), the Oncology Care Model (OCM),...
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the evolution and challenges of alternative payment models, including accountable care organizations (ACOs), the Oncology Care Model (OCM),...
In this Breaking Down Health...
01/09/2025
Cancer Care Business Exchange
Patel Headshot
Interview
Evolving Clinical Pathways for Perioperative Strategies in Resectable NSCLC
01/09/2025
In this interview, Sandip Patel, MD, discusses the evolution of clinical pathways for non-small cell lung cancer (NSCLC), including the integration of perioperative strategies, the potential of immunotherapy in earlier stages, the role of...
In this interview, Sandip Patel, MD, discusses the evolution of clinical pathways for non-small cell lung cancer (NSCLC), including the integration of perioperative strategies, the potential of immunotherapy in earlier stages, the role of...
In this interview, Sandip Patel,...
01/09/2025
Journal of Clinical Pathways
Interview
Transforming Treatment Pathways for Endometrial Cancer
12/20/2024
In this interview, Floortje Backes, MD, The Ohio State University College of Medicine, discusses advancements in novel treatments, the impact of molecular classifications, evolving surgical approaches, barriers to standardizing care, and...
In this interview, Floortje Backes, MD, The Ohio State University College of Medicine, discusses advancements in novel treatments, the impact of molecular classifications, evolving surgical approaches, barriers to standardizing care, and...
In this interview, Floortje...
12/20/2024
Journal of Clinical Pathways
Lisa Herms
Conference Coverage
Impact of Bispecific Antibodies on Treatment Patterns and Patient Characteristics in Multiple Myeloma
12/19/2024
Learn about the real-world utilization of bispecific antibodies for relapsed/refractory multiple myeloma in the US community oncology setting, showing promising results in patient characteristics and uptake, with potential impact on patient...
Learn about the real-world utilization of bispecific antibodies for relapsed/refractory multiple myeloma in the US community oncology setting, showing promising results in patient characteristics and uptake, with potential impact on patient...
Learn about the real-world...
12/19/2024
Journal of Clinical Pathways
Shaverdian Headshot
Interview
Incorporating Precision Medicine and AI Into NSCLC Radiation Approaches
12/19/2024
In this interview, Narek Shaverdian, MD, discusses the evolving role of radiation therapy in NSCLC treatment, highlighting advancements in precision medicine, the integration of AI, and promising research aimed at improving patient outcomes.
In this interview, Narek Shaverdian, MD, discusses the evolving role of radiation therapy in NSCLC treatment, highlighting advancements in precision medicine, the integration of AI, and promising research aimed at improving patient outcomes.
In this interview, Narek...
12/19/2024
Journal of Clinical Pathways

Newsfeed

FDA Approval
FDA Approves Erdafitinib for Patients With Locally Advanced/Metastatic Urothelial Carcinoma Harboring FGFR3 Alterations
01/20/2024
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1...
01/20/2024
Oncology
News
Endoluminal Gemcitabine-Docetaxel as a Renal-Sparing Option for Select Patients With High Grade Upper-Tract Urothelial Carcinoma
01/08/2024
According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.
According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.
According to a retrospective...
01/08/2024
Oncology
Conference Coverage
Outcomes and Costs of Treatment for Patients With Metastatic Upper Tract Urothelial Carcinoma
03/31/2023
At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
At the 2023 ASCO GU Cancers...
03/31/2023
Journal of Clinical Pathways
News
Increased Costs Associated With Excessive Surveillance and Treatment For Non–Muscle-Invasive Bladder Cancer
04/14/2022
The annual median one-year cost of care for low-grade, non–muscle-invasive bladder cancer increased by 60%, or nearly $20,000, from 2004 to 2013, according to a population-based cohort study.
The annual median one-year cost of care for low-grade, non–muscle-invasive bladder cancer increased by 60%, or nearly $20,000, from 2004 to 2013, according to a population-based cohort study.
The annual median one-year cost...
04/14/2022
Journal of Clinical Pathways
News
Racial Disparities in Immune Checkpoint Inhibitor Treatment and Survival Among Patients With NSCLC
01/15/2025
Disparities in immune checkpoint inhibitor utilization and survival based on race and socioeconomic factors in patients with metastatic non-small cell lung cancer (NSCLC) underscore the need for improved access to care for vulnerable...
Disparities in immune checkpoint inhibitor utilization and survival based on race and socioeconomic factors in patients with metastatic non-small cell lung cancer (NSCLC) underscore the need for improved access to care for vulnerable...
Disparities in immune checkpoint...
01/15/2025
Journal of Clinical Pathways
News
Social Risks Lower Rates of Preventive Cancer Screenings
01/09/2025
A recent study published in JNCI Cancer Spectrum investigated the pathways through which social risks affect screening outcomes for breast, cervical, and colorectal cancer (CRC) in patients served in community-based clinics across the US.
A recent study published in JNCI Cancer Spectrum investigated the pathways through which social risks affect screening outcomes for breast, cervical, and colorectal cancer (CRC) in patients served in community-based clinics across the US.
A recent study published in JNCI...
01/09/2025
Journal of Clinical Pathways
News
A Deep Learning Model for Predicting Immune Checkpoint Inhibitor Efficacy in NSCLC
01/08/2025
Researchers developed and validated a deep learning model, Deep-IO, designed to predict the efficacy of immune checkpoint inhibitors (ICIs) in treating advanced non-small cell lung cancer (NSCLC), according to a study published in JAMA...
Researchers developed and validated a deep learning model, Deep-IO, designed to predict the efficacy of immune checkpoint inhibitors (ICIs) in treating advanced non-small cell lung cancer (NSCLC), according to a study published in JAMA...
Researchers developed and...
01/08/2025
Journal of Clinical Pathways
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
Refining Risk Stratification for Myelofibrosis Using Real-World Data
12/20/2024
Despite advancements in understanding the molecular basis of myelofibrosis (MF), a rare and complex bone marrow disorder, predicting disease outcomes and tailoring treatments remains challenging. A study published in Cancers used real-world...
Despite advancements in understanding the molecular basis of myelofibrosis (MF), a rare and complex bone marrow disorder, predicting disease outcomes and tailoring treatments remains challenging. A study published in Cancers used real-world...
Despite advancements in...
12/20/2024
Journal of Clinical Pathways
News
Travel and Financial Burdens Play a Role in Cancer Care
12/19/2024
The joint stressors of travel burdens and financial hardship can affect the care patients with cancer receive.
The joint stressors of travel burdens and financial hardship can affect the care patients with cancer receive.
The joint stressors of travel...
12/19/2024
Journal of Clinical Pathways
News
An Evaluation of Endometrial Cancer Guidelines for Optimal Patient Care
12/17/2024
A review published in Cancers compares multiple guidelines on managing endometrial cancer, emphasizing the importance of consistent protocols and the role of molecular classification in optimizing treatment for postmenopausal women.
A review published in Cancers compares multiple guidelines on managing endometrial cancer, emphasizing the importance of consistent protocols and the role of molecular classification in optimizing treatment for postmenopausal women.
A review published in Cancers...
12/17/2024
Journal of Clinical Pathways
News
Cancer Predisposition Genes Found in 1 in 10 Patients With Multiple Myeloma
12/17/2024
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients...
12/17/2024
Journal of Clinical Pathways
News
Exploring Lipid Metabolism Pathways in Endometrial Cancer Growth and Metastasis
12/17/2024
Metabolic disorders such as obesity and dyslipidemia are closely linked to diagnosis and risk of endometrial cancer (EC). With incidence and mortality rates on the rise, a study in Cell Communication and Signaling analyzed how lipid...
Metabolic disorders such as obesity and dyslipidemia are closely linked to diagnosis and risk of endometrial cancer (EC). With incidence and mortality rates on the rise, a study in Cell Communication and Signaling analyzed how lipid...
Metabolic disorders such as...
12/17/2024
Journal of Clinical Pathways
News
Study Highlights Risks and Outcomes of Radiation Therapy in Patients With Endometrial Cancer
12/13/2024
Patients with endometrial cancer who receive adjuvant radiation therapy (RT) may face an increased risk of developing certain second primary malignancies (SPMs).
Patients with endometrial cancer who receive adjuvant radiation therapy (RT) may face an increased risk of developing certain second primary malignancies (SPMs).
Patients with endometrial cancer...
12/13/2024
Journal of Clinical Pathways

Interactive Features

SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways
Nov-Dec 2024 Issue Cover

Current Issue

December 2024
Volume 10
Issue 6
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

FDA Approval
FDA Approves Erdafitinib for Patients With Locally Advanced/Metastatic Urothelial Carcinoma Harboring FGFR3 Alterations
01/20/2024
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1...
01/20/2024
Oncology
News
Endoluminal Gemcitabine-Docetaxel as a Renal-Sparing Option for Select Patients With High Grade Upper-Tract Urothelial Carcinoma
01/08/2024
According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.
According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.
According to a retrospective...
01/08/2024
Oncology
David Bogumil
Videos
Multiple Ethnicities Study Explores A Connection Between Type 2 Diabetes and Urinary Bladder Cancer
10/12/2023
David Bogumil, PhD, details his findings on a connection between type 2 diabetes and urinary bladder cancer for African American, European American, Japanese American, Latin American, and Native Hawaiian populations.
David Bogumil, PhD, details his findings on a connection between type 2 diabetes and urinary bladder cancer for African American, European American, Japanese American, Latin American, and Native Hawaiian populations.
David Bogumil, PhD, details his...
10/12/2023
Journal of Clinical Pathways
Conference Coverage
Outcomes and Costs of Treatment for Patients With Metastatic Upper Tract Urothelial Carcinoma
03/31/2023
At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
At the 2023 ASCO GU Cancers...
03/31/2023
Journal of Clinical Pathways
Guideline Updates
NCCN Updates Therapy Guidelines in Bladder Cancer
08/26/2022
NCCN Guidelines Panel for Bladder Cancer presented data evaluating new treatment options in bladder cancer, as well as relevant updates to the NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer.
NCCN Guidelines Panel for Bladder Cancer presented data evaluating new treatment options in bladder cancer, as well as relevant updates to the NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer.
NCCN Guidelines Panel for...
08/26/2022
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use